/
MLTX
$19.91+$0.01 (+0.05%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.7B
84M shares
52-week range
$5.95 – $62.75
25% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$7.66
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $5.0K | $0 | $0 | $0 | $2.6M |
| Gross profit | $0 | −$5.0K | $0 | $0 | $0 | −$2.6M |
| Gross margin | — | — | — | — | — | — |
| R&D | $0 | $35.5M | $42.0M | $31.8M | $112.8M | $202.9M |
| Operating income | −$105.8K | −$53.6M | −$65.1M | −$54.1M | −$143.1M | −$244.8M |
| EBITDA | −$90.8K | −$53.6M | −$64.3M | −$43.6M | −$119.6M | −$219.8M |
| Net income | −$90.8K | −$53.6M | −$50.0M | −$36.0M | −$118.9M | −$227.3M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.01 | -1.45 | -2.20 | -0.73 | -1.89 | -3.53 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-3.83 | $-4.29–$-3.36 | 8 |
| 2027 | $23M | $-3.64 | $-4.34–$-2.95 | 8 |
| 2028 | $136M | $-2.90 | $-4.29–$-1.38 | 7 |
| 2029 | $443M | $-0.83 | $-0.95–$-0.71 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.08
Price
$19.91
Implied downside
-79%
Peer comparison
MoonLake Immunotherapeutics Class A Ordinary Shares
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
www.moonlaketx.com- Employees
- 130
- IPO / List date
- Apr 6, 2022
- HQ
- ZUG, V8
Held by traders on TradeandTell
No one on the platform currently holds MLTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 276,772 | $5.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MLTX yet.
